Compare THRY & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | ORGO |
|---|---|---|
| Founded | 2012 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 166.0M |
| IPO Year | 2020 | 2016 |
| Metric | THRY | ORGO |
|---|---|---|
| Price | $1.15 | $1.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $4.00 | $2.00 |
| AVG Volume (30 Days) | 541.4K | ★ 631.0K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.50 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $785,015,000.00 | $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $1.18 | $0.99 |
| 52 Week High | $12.57 | $7.08 |
| Indicator | THRY | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 21.60 | 17.22 |
| Support Level | N/A | N/A |
| Resistance Level | $4.22 | $2.69 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.12 | 4.89 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.